tovecimig

Multispecific antibody

Also known as CTX-009

Phase 2/3topline reported

Evidence outlook · registrational

Biliary Tract Cancer: topline reported 2026-04-27

No completed mid-stage readout is on record. The sponsor reported topline results on 2026-04-27 (COMPANION-002 secondary endpoints of tovecimig: PFS improved, overall survival not improved). The announcement is listed under Regulatory events.

Featured evidence outside this drug's tracked markets:NCT07662031 · Colorectal Cancer · Phase 2 · ungraded

Source for the program status

Company guidance: regulatory filing expected later this year (Compass Therapeutics, 6 Aug 2026). “In April 2026, the Company announced positive data from its Phase 2/3 study of tovecimig, which it plans to include in a BLA submission later this year.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Biliary Tract Cancer
NCT05506943 · Compass Therapeutics
2023-01-09 – 2027-08-31 · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
What this study did
Phase 2 (2)
Other / comorbidity
NCT07662031 · Washington University School of Medicine
2026-12-31 – 2032-12-31 · Colorectal Cancer, Metastatic Colorectal Cancer
What this study did
NCT05513742 · Compass Therapeutics
2022-12-08 – 2025-05-15 · Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
What this study did
Phase 1/2 (3)
Biliary Tract Cancer
NCT06548412 · M.D. Anderson Cancer Center
2025-01-22 – 2029-05-01 · Metastatic Biliary Tract Cancer
What this study did
NCT04492033 · Handok Inc.
2020-06-22 – 2025-01-09 · P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
What this study did
Other / comorbidity
NCT07392957 · Washington University School of Medicine
2026-06-16 – 2031-06-30 · Glioblastoma
What this study did

Competitive landscape

This drug's own stage for Biliary Tract Cancer: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tovecimig: this drugPhase 2/3Multispecific antibodyDLL4 x VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
ZanidatamabApprovedMultispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
Futibatinib (Lytgobi)Phase 3Small moleculeFGFR (FGFR1/2/3/4)not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
RamucirumabPhase 2Monoclonal antibodyVEGFR2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow tovecimig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2027-05-01 · NCT06548412 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3Biliary Tract CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05506943 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2029-06-30 · NCT07392957 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Colorectal Cancer, Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07662031 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 April 2026Topline resultCOMPANION-002 secondary endpoints of tovecimig: PFS improved, overall survival not improved
Compass Therapeutics · Source ↗
1 April 2025Topline resultCOMPANION-002 Phase 2/3 primary endpoint met